Brief Summary

ST-segment elevation myocardial infarction(STEMI) remains a major cause of morbidity and mortality worldwide, despite of the early reperfusion therapy, including fibrinolysis, primary percutaneous coronary intervention (PCI),and standardized medical treatment.To improve the prognosis of STEMI patients, the management in their hospitalization should be optimized, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through PCI (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as lipid-lowering therapy. This study aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Trial Health

At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date

Enrollment

2,000

participants targeted

Target at P75+ for all trials

Timeline

Completed

Started Sep 2018

Longer than P75 for all trials

Geographic Reach

1 country

7 active sites

Status

unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

6 years study duration

Study Start

First participant enrolled

September 12, 2018

Completed

3.8 years until next milestone

First Submitted

Initial submission to the registry

July 2, 2022

Completed

9 days until next milestone

First Posted

Study publicly available on registry

July 11, 2022

Completed

1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 17, 2023

Completed

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 17, 2024

Completed

Last Updated

July 11, 2022

Status Verified

July 1, 2022

Enrollment Period

5 years

First QC Date

July 2, 2022

Last Update Submit

July 6, 2022

Conditions

ST Elevation Myocardial Infarction

Keywords

Acute Myocardial InfarctionCardiac RemodellingHeart Failure

Outcome Measures

Primary Outcomes (3)

MACE
Major adverse cardiovascular events(MACE) in one year follow-up
0-1 year
Left Ventricular Function
Left ventricular end diastolic volume(LVEDV),Left ventricular end systolic volume(LVESE),Left ventricular ejection fraction(LVEF) changes within one year follow-up
1 month, 6month and 1 year
Coronary angiography
The pathological changes in culprit vessels in 1 year
1 year

Other Outcomes (1)

Synchronized analysis of phonocardiogram and electrocardiogram
1 day, 1 month, 6 months, 1 year

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

This is multi-center cohort study. Patients with acute ST elevation myocardial infarction undergo percutaneous coronary intervention within 12 hours of symptom onset at Ruijin Hospital, Minhang district Center Hospital, Yangpu district Center Hospital, Putuo district Center hospital,Jiading district Center Hospital, Fengxian district Center Hospital,and Shanghai Fifth people's Hospital, Shanghai, China are consecutively enrolled.

You may qualify if:

ST elevation myocardial infarction
Coronary angiography and percutaneous coronary intervention within 12 hours of symptom onset
Capable and willing to provide informed conset and capable of completing study visits

You may not qualify if:

Cardiovascular shock at admission
Severe physical disability
Active malignant tumors
Active autoimmune diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Ruijin Hospitallead

Study Sites (7)

Ruijin hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China

RECRUITING

Shanghai Fengxian District Central Hospital